These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38754401)

  • 1. Association of the Complement Factor H Y402H Polymorphism and Response to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration: An Updated Meta-Analysis.
    Roshanshad A; Moosavi SA; Arevalo JF
    Ophthalmic Res; 2024; 67(1):358-386. PubMed ID: 38754401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis.
    Hong N; Shen Y; Yu CY; Wang SQ; Tong JP
    Acta Ophthalmol; 2016 Jun; 94(4):334-45. PubMed ID: 27151934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.
    Chen G; Tzekov R; Li W; Jiang F; Mao S; Tong Y
    Sci Rep; 2015 Sep; 5():14517. PubMed ID: 26411831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.
    Brantley MA; Fang AM; King JM; Tewari A; Kymes SM; Shiels A
    Ophthalmology; 2007 Dec; 114(12):2168-73. PubMed ID: 18054635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Association between Y402H, E318D and R102G polymorphisms of complement proteins genes and the response to intravitreal anti-VEGF treatment in patients with neovascular age-related macular degeneration].
    Kubicka-Trząska A; Karska-Basta I; Kobylarz J; Dziedzina S; Sanak M; Romanowska-Dixon B
    Klin Oczna; 2016; 118(2):114-21. PubMed ID: 29912491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of risk genotypes of ARMS2/LOC387715 A69S and CFH Y402H with age-related macular degeneration with and without reticular pseudodrusen: a meta-analysis.
    Jabbarpoor Bonyadi MH; Yaseri M; Nikkhah H; Bonyadi M; Soheilian M
    Acta Ophthalmol; 2018 Mar; 96(2):e105-e110. PubMed ID: 28593728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis.
    Chen H; Yu KD; Xu GZ
    PLoS One; 2012; 7(8):e42464. PubMed ID: 22905135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Variants of Complement Factor H Y402H (rs1061170), C2 R102G (rs2230199), and C3 E318D (rs9332739) and Response to Intravitreal Anti-VEGF Treatment in Patients with Exudative Age-Related Macular Degeneration.
    Kubicka-Trząska A; Żuber-Łaskawiec K; Dziedzina S; Sanak M; Romanowska-Dixon B; Karska-Basta I
    Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630075
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of ARMS2/LOC387715 A69S and CFH Y402H risk effect in wet-type age-related macular degeneration: a meta-analysis.
    Jabbarpoor Bonyadi MH; Yaseri M; Nikkhah H; Bonyadi M; Nazari R; Soheilian M
    Int Ophthalmol; 2019 Apr; 39(4):949-956. PubMed ID: 29423786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
    Mohamad NA; Ramachandran V; Ismail P; Mohd Isa H; Chan YM; Ngah NF; Md Bakri N; Ching SM; Hoo FK; Wan Sulaiman WA; Inche Mat LN; Hazmi Mohamed M
    Bosn J Basic Med Sci; 2018 Aug; 18(3):260-267. PubMed ID: 29579408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab.
    Dikmetas O; Kadayıfcılar S; Eldem B
    Mol Vis; 2013; 19():2571-8. PubMed ID: 24367156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of genetic base in the treatment of age-related macular degeneration.
    Gourgouli K; Gourgouli I; Tsaousis G; Spai S; Niskopoulou M; Efthimiopoulos S; Lamnissou K
    Int Ophthalmol; 2020 Apr; 40(4):985-997. PubMed ID: 31916060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Single-Nucleotide Polymorphisms in Age-Related Macular Degeneration With Pseudodrusen: Secondary Analysis of Data From the Comparison of AMD Treatments Trials.
    Lin LY; Zhou Q; Hagstrom S; Maguire MG; Daniel E; Grunwald JE; Martin DF; Ying GS;
    JAMA Ophthalmol; 2018 Jun; 136(6):682-688. PubMed ID: 29801032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population.
    Medina FMC; Motta AALD; Takahashi WY; Carricondo PC; Motta MMDS; Melo MB; Vasconcellos JPC
    Ophthalmic Res; 2019; 61(3):168-173. PubMed ID: 28641277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of ARMS2/LOC387715 A69S, CFH Y402H, and CFH I62V polymorphisms with retinal angiomatous proliferation compared with typical age-related macular degeneration: a meta-analysis.
    Jabbarpoor Bonyadi MH; Yaseri M; Bonyadi M; Soheilian M
    Int Ophthalmol; 2017 Dec; 37(6):1397-1409. PubMed ID: 28005184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-related macular degeneration and association of CFH Y402H and LOC387715 A69S polymorphisms in a Turkish population.
    Soysal Y; Inan UÜ; Küsbeci T; Imirzalioğlu N
    DNA Cell Biol; 2012 Mar; 31(3):323-30. PubMed ID: 21790300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population.
    Kang HK; Yoon MH; Lee DH; Chin HS
    Korean J Ophthalmol; 2012 Dec; 26(6):414-22. PubMed ID: 23204795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN
    Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CFH Y402H and VEGF Polymorphisms and Anti-VEGF Treatment Response in Exudative Age-Related Macular Degeneration.
    Kepez Yildiz B; Ozdek S; Ergun MA; Ergun S; Yaylacioglu Tuncay F; Elbeg S
    Ophthalmic Res; 2016; 56(3):132-8. PubMed ID: 27404493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodynamic therapy in VEGF inhibition non-responders-Pharmacogenetic study in age-related macular degeneration assessed with swept-source optical coherence tomography.
    Teper SJ; Nowinska A; Pilat J; Wylegala E
    Photodiagnosis Photodyn Ther; 2016 Mar; 13():108-113. PubMed ID: 26780119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.